Breaking News

Over a quarter ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Trinity Biotech reports Q3 revenue $24.6M, one est. $24.5M » 08:47
10/16/19
10/16
08:47
10/16/19
08:47
TRIB

Trinity Biotech

$0.99 /

+0.0965 (+10.80%)

Ronan O'Caoimh, CEO…

Ronan O'Caoimh, CEO said "As anticipated revenues were stronger this quarter, being 4% higher than the equivalent period last year and over 9% higher than quarter 2 of this year. Point-of-care revenues were higher due to increased sales of HIV products in Africa. Meanwhile, Autoimmune and Diabetes revenues also grew, with the latter being driven by particularly strong instrument placements during the quarter. Further revenue growth will be derived from our entry into to the HIV screening market with our TrinSreen product, which we expect to submit to the WHO in January next, with approval to follow during 2020. Given the quality of this product and our knowledge and experience of the African HIV market, we are ideally positioned to take a meaningful share of this substantial market."

ShowHide Related Items >><<
Hot Stocks
Trinity CEO says development of automated slide reader 'progressing well' » 08:37
08/20/19
08/20
08:37
08/20/19
08:37
TRIB

Trinity Biotech

$1.75 /

+0.12 (+7.36%)

Ronan O'Caoimh, CEO…

Ronan O'Caoimh, CEO of Trinity, said, "Revenues were down by $2.5m this quarter and whilst this was disappointing it was largely due to the fluctuating nature of our HIV revenues and to a lesser extent the reduction in the level of public health expenditure being allocated to HIV testing in the USA. On a more positive note our Clinical Laboratory revenues were broadly flat on a constant currency basis. As has been the case in all of our most recent quarters we have continued to see strong growth in our Diabetes and Autoimmunity product lines, although this growth was offset by lower Lyme and Fitzgerald revenues. I would like to highlight the company's strong R&D product pipeline which will be key to driving future revenue growth. In particular, our TrinScreen product, which will mark the company's entry into the $140m African HIV screening market, has the clear potential to transform the company from both a revenue and profitability perspective. Development of our new automated slide reader is progressing well and when launched will be a major boost to our already growing autoimmunity franchise. These come on the back of the Premier Resolution and Tri-Stat 2 product launches, which are already generating incremental haemoglobin revenues."

ShowHide Related Items >><<

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.